Kristian Cibulskis

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/12183177/publications.pdf

Version: 2024-02-01

64 papers	98,395 citations	19657 61 h-index	110387 64 g-index
66 all docs	66 docs citations	66 times ranked	124346 citing authors

#	Article	IF	Citations
1	Evaluating drug targets through human loss-of-function genetic variation. Nature, 2020, 581, 459-464.	27.8	115
2	The mutational constraint spectrum quantified from variation in 141,456 humans. Nature, 2020, 581, 434-443.	27.8	6,140
3	Transcript expression-aware annotation improves rare variant interpretation. Nature, 2020, 581, 452-458.	27.8	142
4	Integrated Molecular Characterization of Uterine Carcinosarcoma. Cancer Cell, 2017, 31, 411-423.	16.8	309
5	Integrative Analysis Identifies Four Molecular and Clinical Subsets in Uveal Melanoma. Cancer Cell, 2017, 32, 204-220.e15.	16.8	642
6	Systematic genomic and translational efficiency studies of uveal melanoma. PLoS ONE, 2017, 12, e0178189.	2.5	34
7	Clonal evolution in patients with chronic lymphocytic leukaemia developing resistance to BTK inhibition. Nature Communications, 2016, 7, 11589.	12.8	285
8	Genomic Classification of Cutaneous Melanoma. Cell, 2015, 161, 1681-1696.	28.9	2,562
9	Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. New England Journal of Medicine, 2015, 372, 2481-2498.	27.0	2,582
10	Prospective Derivation of a Living Organoid Biobank of Colorectal Cancer Patients. Cell, 2015, 161, 933-945.	28.9	1,710
11	Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets. Cancer Discovery, 2015, 5, 1164-1177.	9.4	821
12	The Molecular Taxonomy of Primary Prostate Cancer. Cell, 2015, 163, 1011-1025.	28.9	2,435
13	Mutations driving CLL and their evolution in progression and relapse. Nature, 2015, 526, 525-530.	27.8	868
14	Comprehensive analysis of cancer-associated somatic mutations in class I HLA genes. Nature Biotechnology, 2015, 33, 1152-1158.	17.5	573
15	The Genetic Landscape of Clinical Resistance to RAF Inhibition in Metastatic Melanoma. Cancer Discovery, 2014, 4, 94-109.	9.4	782
16	Integrated Genomic Characterization of Papillary Thyroid Carcinoma. Cell, 2014, 159, 676-690.	28.9	2,318
17	Sporadic hemangioblastomas are characterized by cryptic VHL inactivation. Acta Neuropathologica Communications, 2014, 2, 167.	5.2	65
18	The Genomic Landscape of Pediatric Ewing Sarcoma. Cancer Discovery, 2014, 4, 1326-1341.	9.4	415

#	Article	IF	Citations
19	Systematic identification of personal tumor-specific neoantigens in chronic lymphocytic leukemia. Blood, 2014, 124, 453-462.	1.4	286
20	MAP Kinase Pathway Alterations in BRAF-Mutant Melanoma Patients with Acquired Resistance to Combined RAF/MEK Inhibition. Cancer Discovery, 2014, 4, 61-68.	9.4	419
21	Widespread Genetic Heterogeneity in Multiple Myeloma: Implications for Targeted Therapy. Cancer Cell, 2014, 25, 91-101.	16.8	847
22	Whole-exome sequencing of circulating tumor cells provides a window into metastatic prostate cancer. Nature Biotechnology, 2014, 32, 479-484.	17.5	495
23	Genetic and Clonal Dissection of Murine Small Cell Lung Carcinoma Progression by Genome Sequencing. Cell, 2014, 156, 1298-1311.	28.9	241
24	Whole-exome sequencing and clinical interpretation of formalin-fixed, paraffin-embedded tumor samples to guide precision cancer medicine. Nature Medicine, 2014, 20, 682-688.	30.7	508
25	Landscape of genomic alterations in cervical carcinomas. Nature, 2014, 506, 371-375.	27.8	708
26	Integrative and Comparative Genomic Analysis of Lung Squamous Cell Carcinomas in East Asian Patients. Journal of Clinical Oncology, 2014, 32, 121-128.	1.6	176
27	RNF43 is frequently mutated in colorectal and endometrial cancers. Nature Genetics, 2014, 46, 1264-1266.	21.4	388
28	Colon cancer-derived oncogenic EGFR G724S mutant identified by whole genome sequence analysis is dependent on asymmetric dimerization and sensitive to cetuximab. Molecular Cancer, 2014, 13, 141.	19.2	24
29	The Somatic Genomic Landscape of Glioblastoma. Cell, 2013, 155, 462-477.	28.9	3,979
30	Somatic mutation of CDKN1B in small intestine neuroendocrine tumors. Nature Genetics, 2013, 45, 1483-1486.	21.4	275
31	Evolution and Impact of Subclonal Mutations in Chronic Lymphocytic Leukemia. Cell, 2013, 152, 714-726.	28.9	1,202
32	Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nature Biotechnology, 2013, 31, 213-219.	17.5	3,934
33	Exome and whole-genome sequencing of esophageal adenocarcinoma identifies recurrent driver events and mutational complexity. Nature Genetics, 2013, 45, 478-486.	21.4	671
34	Punctuated Evolution of Prostate Cancer Genomes. Cell, 2013, 153, 666-677.	28.9	1,107
35	Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature, 2013, 499, 214-218.	27.8	4,761
36	The genetic landscape of high-risk neuroblastoma. Nature Genetics, 2013, 45, 279-284.	21.4	990

#	Article	IF	Citations
37	A homozygous missense mutation inHERC2associated with global developmental delay and autism spectrum disorder. Human Mutation, 2012, 33, 1639-1646.	2.5	90
38	Mapping the Hallmarks of Lung Adenocarcinoma with Massively Parallel Sequencing. Cell, 2012, 150, 1107-1120.	28.9	1,591
39	Medulloblastoma exome sequencing uncovers subtype-specific somatic mutations. Nature, 2012, 488, 106-110.	27.8	675
40	Melanoma genome sequencing reveals frequent PREX2 mutations. Nature, 2012, 485, 502-506.	27.8	671
41	Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. Nature Genetics, 2012, 44, 1104-1110.	21.4	1,186
42	Absolute quantification of somatic DNA alterations in human cancer. Nature Biotechnology, 2012, 30, 413-421.	17.5	1,710
43	Genetic Mapping and Exome Sequencing Identify Variants Associated with Five Novel Diseases. PLoS ONE, 2012, 7, e28936.	2.5	254
44	Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nature Genetics, 2012, 44, 685-689.	21.4	1,300
45	A Landscape of Driver Mutations in Melanoma. Cell, 2012, 150, 251-263.	28.9	2,247
46	Sequence analysis of mutations and translocations across breast cancer subtypes. Nature, 2012, 486, 405-409.	27.8	1,107
47	A remarkably simple genome underlies highly malignant pediatric rhabdoid cancers. Journal of Clinical Investigation, 2012, 122, 2983-2988.	8.2	347
48	SF3B1and Other Novel Cancer Genes in Chronic Lymphocytic Leukemia. New England Journal of Medicine, 2011, 365, 2497-2506.	27.0	1,021
49	Genomic sequencing of colorectal adenocarcinomas identifies a recurrent VTI1A-TCF7L2 fusion. Nature Genetics, 2011, 43, 964-968.	21.4	270
50	The Mutational Landscape of Head and Neck Squamous Cell Carcinoma. Science, 2011, 333, 1157-1160.	12.6	2,225
51	The functional spectrum of low-frequency coding variation. Genome Biology, 2011, 12, R84.	9.6	173
52	A framework for variation discovery and genotyping using next-generation DNA sequencing data. Nature Genetics, 2011, 43, 491-498.	21.4	10,018
53	The genomic complexity of primary human prostate cancer. Nature, 2011, 470, 214-220.	27.8	1,107
54	Initial genome sequencing and analysis of multiple myeloma. Nature, 2011, 471, 467-472.	27.8	1,288

#	Article	IF	Citations
55	A scalable, fully automated process for construction of sequence-ready human exome targeted capture libraries. Genome Biology, 2011, 12, R1.	9.6	547
56	Temporal Dissection of Tumorigenesis in Primary Cancers. Cancer Discovery, 2011, 1, 137-143.	9.4	240
57	ContEst: estimating cross-contamination of human samples in next-generation sequencing data. Bioinformatics, 2011, 27, 2601-2602.	4.1	235
58	Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy. Nature Genetics, 2010, 42, 715-721.	21.4	642
59	Targeted Exon Sequencing by Inâ€Solution Hybrid Selection. Current Protocols in Human Genetics, 2010, 66, Unit 18.4.	3.5	40
60	Integrative analysis of the melanoma transcriptome. Genome Research, 2010, 20, 413-427.	5.5	248
61	The Genome Analysis Toolkit: A MapReduce framework for analyzing next-generation DNA sequencing data. Genome Research, 2010, 20, 1297-1303.	5.5	21,358
62	Exome Sequencing,ANGPTL3Mutations, and Familial Combined Hypolipidemia. New England Journal of Medicine, 2010, 363, 2220-2227.	27.0	640
63	Somatic mutations affect key pathways in lung adenocarcinoma. Nature, 2008, 455, 1069-1075.	27.8	2,694
64	Drug-sensitiveFGFR2mutations in endometrial carcinoma. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 8713-8717.	7.1	329